The depository receipt holders of Implantica AG, reg. no. FL-0002.629.889-3, are hereby invited to attend the annual general meeting to be held on Thursday, May 15, 2025, at 14:00 at Hotel Kommod, Industriering 14, 9491 Ruggell, Liechtenstein.

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop™ for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces another Center of Excellence in Spain to offer RefluxStop™, H. Univ. Marqués de Valdecilla, in Cantabria region in Spain.

Implantica AG (publ), a med-tech company at the forefront of bringing advanced technology into the body, is publishing its annual report for the fiscal year 2024. The annual report is now available on the company’s website.

Implantica AG (publ.), a MedTech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop™ for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces a new article from Germany in the well-respected Journal of Laparoendoscopic & Advanced Surgical Techniques (https://pubmed.ncbi.nlm.nih.gov/40152889/) showing excellent RefluxStop™ results in a real-world setting, akin to those achieved in the CE mark study.

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop™ for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces that RefluxStop™ attracted significant attention and discussion at the Society of American Gastrointestinal Endoscopic Surgeons (SAGES) Annual Meeting earlier this month in Long Beach, California.

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop™ for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces that the RefluxStop™ procedure is now being performed at the Hospital Vithas 9 de Octubre, in Valencia, Spain.

RefluxStop™ FDA Milestone

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including a unique device RefluxStop™ for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces that U.S. FDA has completed its review of the PMA Module 2 submission and provided its feedback, in which the company sees no barrier for responding.

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including a unique device RefluxStop™ for the treatment of acid reflux, a treatment field with 1 billion sufferers, is pleased to announce that the FDA has accepted Module 1 of the company’s premarket approval (PMA) application, and that this module is now considered closed.

Implantica AG (publ) invites investors to a presentation of the Year-end Report (Q4 2024) at 15:00 CET on February 14. The Year-end Report (Q4 2024) will be published at 8:00 a.m. CET on the same day.